SITC 2024 | Investigating the mechanism of action for 2141-V11 in the tumor microenvironment
Juan Osorio, MD, Memorial Sloan Kettering Cancer Center, The Rockefeller University, New York, NY, talks about the impact of intratumoral administration of 2141-V11 in inducing tumor regression. The increased interaction between dendritic cells and CD4 or CD8 T-cells, and the formation of tertiary lymphoid structures (TLS) upon 2141-V11 activity in injected and non-injected lesions has provided key insights on the mechanism of action for Fc-enhanced immunotherapy. Further studies are investigating the mechanism of action for 2141-V11 in local and distal lesions. This interview took place at the 39th Annual Meeting Society for Immunotherapy of Cancer 2024, Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
